AffyImmune Therapeutics, Inc.

Quick facts

Phase 1 pipeline

• AIC100 CAR T Cells · Oncology
  Chimeric antigen receptor T cells targeting CD19

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• AffyImmune Therapeutics, Inc. portfolio CI brief
• AffyImmune Therapeutics, Inc. pipeline updates RSS